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Background: Amyotrophic lateral sclerosis (ALS) is a primary progressive neurodegenerative disease characterised
by neuronal loss of lower motor neurons (in the spinal cord and brainstem) and/or upper motor neurons (in the
motor cortex) and subsequent denervation atrophy of skeletal muscle.
Aim: A comprehensive examination of muscle pathology from a cohort of clinically confirmed ALS patients,
including an investigation of inflammation, complement activation, and deposition of abnormal proteins in order to
compare them with findings from an age-matched, control group.
Material and methods: 31 muscle biopsies from clinically confirmed ALS patients and 20 normal controls
underwent a comprehensive protocol of histochemical and immunohistochemical stains, including HLA-ABC, C5b-9,
p62, and TDP-43.
Results: Neurogenic changes were confirmed in 30/31 ALS cases. In one case, no neurogenic changes could be
detected. Muscle fibre necrosis was seen in 5/31 cases and chronic mononuclear inflammatory cell infiltration in
5/31 (2 of them overlapped with those showing muscle necrosis). In four biopsies there was an increase in the
proportion of cytochrome oxidase (COX) negative fibres (2-3%). p62 faintly stained cytoplasmic bodies in eight
cases and none were immunoreactive to TDP-43.
Conclusion: This large series of muscle biopsies from patients with ALS demonstrates neurogenic atrophy is a
nearly uniform finding and that mild mitochondrial abnormalities and low-grade inflammation can be seen and do
not rule out the diagnosis of ALS. These findings could lend support to the notion that ALS is a complex and
heterogeneous disorder.
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Amyotrophic lateral sclerosis (ALS) is a progressive neu-
rodegenerative disease characterised primarily by degen-
eration of upper and lower motor neurons (LMN) in the
cerebral cortex, spinal cord and brainstem. This leads to
relentlessly progressive weakness and widespread flaccid* Correspondence: safa.al-sarraj@nhs.net; Andrewking@nhs.net
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unless otherwise stated.paralysis and/or spasticity, depending on the predomin-
ance of upper versus LMN disease [1,2].
The presentation is heterogeneous and may begin with
appendicular weakness, bulbar weakness or respiratory
muscle weakness. Neuro-imaging is useful in excluding
other diseases. Electromyography (EMG) is used to
support the clinical findings, possibly allowing a more
accurate and early diagnosis, as it can detect denervation
sometimes before clinical signs are evident. (El Escorial
and Awaji criteria) [3].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Al-Sarraj et al. Acta Neuropathologica Communications  (2014) 2:165 Page 2 of 9Pathologically, ALS is characterised by neuronal loss
in the anterior horn of the spinal cord, brainstem nuclei,
and Betz cells of the motor cortex, and also by the de-
position of abnormal ubiquitinated inclusions immuno-
reactive to TDP-43 [4]. But these central nervous system
changes are only accessible post mortem. In contrast, the
muscle pathology of denervation atrophy, such as angular,
atrophic fibres, grouped atrophy and fibre type grouping
can be assessed pre-mortem and may lead to earlier diag-
nostic certainty or provide a means to assess possible
treatment impact on disease progression. It is therefore
very important to understand muscle pathology in ALS
for clinical trials in this field.
The aetiology and pathogenesis of the neuronal death
in ALS remains poorly understood. The majority of ALS
cases are sporadic while 10-15% are familial. Mutations
have been identified in genes encoding for Cu/Zn super-
oxide dismutase (SOD1), VAMP (vesicle associated mem-
brane protein), angiogenin (ANG), TDP-43 and Fused in
sarcoma (FUS), Optineurin (OPTN), and more recently
C9orf72 (linked to chromosome 9) [5-10].
There are several theories to explain the neurodegenera-
tive processes including glutamate-induced excitotoxicity,
axonal transport impairment, proteasome dysfunction,
aberrant functioning of glial cells, alterations in muscle
and neuromuscular junction [11,12], and mitochondrial
dysfunction [13-18]. There are reports of abnormal aggre-
gation of mitochondria and impaired respiratory chain
function (particularly in complex 1) in experimental mice
with SOD1 mutation [5,19-21]. However, the role of
mitochondrial abnormalities in the pathogenesis of ALS
is unknown [22]. Although some reports suggest mito-
chondrial dysfunction in the skeletal muscle and a signifi-
cant increase in mitochondrial DNA deletions indicate a
primary defect in muscles of ALS patients; others suggest
that mitochondrial dysfunction is a consequence of the
motor neuron cell death [8,11,23-28]. The majority of re-
ports describing the muscle pathology of ALS patients are
case reports; systematic investigations of muscle pathology
in a large cohort of patient with ALS are few [29-33].
We report the pathological changes in the skeletal
muscle in a cohort of 31 patients with ALS according
to El Escorial criteria and compare them with muscle
biopsies from 20 age-matched controls.
Material and methods
Study populations
A total of 32 patients with ALS (age range 27–75 years,
mean age 54.8 years) were recruited as part of a method-
ology study (NOG111329) to assess biomarkers of ALS;
31 subjects provided muscle biopsy samples. ALS pa-
tients with a diagnosis of clinically definite or probable
ALS (according to El Escorial diagnostic criteria, revised
according to the Airlie House Conference 1998) wererecruited at 3 ALS centres. Inclusion criteria included
onset of muscle weakness within 24 months of study entry
and MRC score in the deltoid muscle of MRC grade 3 or
4. Subjects with evidence of other neuromuscular disor-
ders were excluded. Twenty healthy volunteers (age range
41–69 years, mean age 55.7 years) were recruited at the
Guy’s Drug Research Unit (GDRU) in London to assess
levels of potential ALS biomarkers in muscle samples
from healthy subjects (NOG113240).
The study protocol, protocol amendments, informed
consent and any other information that required pre-
approval were reviewed and approved by a national,
regional or investigational centre ethics committee or an
institutional review board. This study was conducted in
accordance with Good Clinical Practice and the guiding
principles of the Declaration of Helsinki, and all subjects
provided written informed consent.
Muscle biopsy procedure
Thirty-one ALS patients and 20 healthy volunteers
underwent open muscle biopsy from the deltoid muscle
according to standard procedures. For ALS patients, the
weaker of the two deltoid muscles was selected. A muscle
specimen of an approximate size of 1.0 cm × 0.5 cm ×
0.5 cm was taken per subject.
Processing muscle biopsy samples
The muscle biopsies were processed freshly (i.e. unfixed)
in the laboratory soon after the surgical removal to mi-
nimize preparative artefact. The muscle biopsy sample
was divided perpendicular to the muscle fibres into two
equally large pieces, one piece for pathological assess-
ment, while the second piece was processed for other
biomarkers (not reported here). The pathology sample
was oriented and fixed transversely to cork discs with
OCT and then snap frozen in iso-pentane cooled on dry
ice. Tissue was transferred to pre-cooled cryotubes and
stored frozen at -80°C.
Histology and immunohistochemistry
Serial cryostat sections were cut from the frozen biopsy
material (7 mm thickness) and stained for H&E, ATPase
9.4, ATPase 4.6, ATPase 4.2, nicotinamide adenine di-
nucleotide tetrazolium reductase (NADH-TR), succinic
dehydrogenase (SDH), cytochrome oxidase (COX) with
and without SDH, Gomori trichrome (GT), acid phos-
phatase (AP), Periodic acid-Schiff (PAS), Periodic acid-
Schiff with diastase (PAS-D), myophosphorylase and
Sudan Black.
Further immunohistochemistry stains were performed
for p62 (BD transduction Labs, clone: 3/p62 LCK Ligand,
dilution 1:150), pTDP-43 (Cosmo Bio Co. LTD, code
TIP-PTD-P02, dilution1:1500), HLA-ABC (Dako, clone:
W6/32, dilution 1:1200) and C5b-9 “membrane attack
Table 1 Summary of muscle pathology in ALS/MND
patients
Age/sex NC Infl Nec COX -ve HLA C5b-9 P62 TDP CK
54 M + + - - - + F + - 350
+ C
54 M + - + - + + F + - 107
75 F + - + 2% + + F + - 114
56 M + - - - - - - - 443
61 F + - - - - - - - 285
57 M + - - - - + F + - 337
27 M + - - - - + F + - 313
45 M + - - - - - - - 151
57 F - + - - - + F - - 47
+ C
36 M + - - - - - - - 143
29 M + - - - - - + - 170
66 M + - - 3% - - - - 82
69 M + - - - - + F - - 267
66 M + - - - + + F - - 119
61 M + - - - - + F - - 807
60 M + - - - - + F - - 295
59 F + + + - - - - - 145
34 M + + + - + + F - - 1386
47 F + - - - - + F - - 108
41 M + - - - - + F - - 238
67 M + - - 1% - + F - - 148
40 M + - - - + + C + - 166
60 F + - - 3% - + F - - 252
61 F + - - 2% - + F - - 99
55 M + - - - - + F - - 391
50 M + + - - - + F - - 963
67 F + - - - - + F + - 52
61 F + - - - - + F - - 318
65 M + - - - - + F - - 150
48 F +/− - + - - - - - 130
67 M + - - - - - - - 425
NC: neurogenic changes; Infl: inflammation; Nec: Necrosis. C: capillaires.
F: fibres.
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(Dako, code M7254M dilution 1:50), CD20(Dako code
M075501, dilution 1:200), CD8(Novocastra code CD8-
295-CE, dilution 1:20), CD 4 (Novocastracode CD4-1f6-
CE-S, dilution 1:20), neonatal myosin (Novocastra code
NCL-MHCn, dilution 1:5) and Utrophin (Novocastra code
NCL-DRP2, dilution 1:100).
Cryostat sections were processed according to the pro-
tocol at the Department of Clinical Neuropathology,
King’s College Hospital London. Slides were interpreted
by a senior Neuropathologist (SALS) blind to clinical
information and findings are summarised in Tables 1
and 2.
Laboratory assessments
Plasma (EDTA) samples were collected from ALS sub-
jects prior to collection of open muscle biopsy samples
and aliquots dispensed and frozen at -80°C. Frozen sam-
ples were shipped to The Doctors Laboratory (TDL) and
an exploratory analysis performed for lactate dehydro-
genase (LDHI2), creatinine (CREJ2) and creatine kinase
(CK) using the Roche Cobas system. Note that sample
stability data was not available to cover the storage time
(>1 year) or conditions (−80°C) for these samples.
Non parametric Mann Whitney test was carried out to
find the correlation between increased CK levels and
muscle fibre necrosis and inflammation.
Results
Thirty of 31 ALS muscle biopsies showed evidence of
neurogenic atrophy with various stages of denervation
and re-innervation of muscle fibres. These included early
changes such as scattered angular, atrophic fibres which
are densely stained with NADH-TR as well as more chro-
nic changes with small and large grouped atrophy and
fibre type grouping. One case showed no clear features of
neurogenic changes but definite ALS on clinical grounds.
There were occasional small fibres and lymphocyte
infiltration limited to the perimysium, however, there was
no endomysial inflammation, the HLA-ABC was not
over-expressed and creatinine kinase was low (CK: 47 IU)
suggesting that the focus of inflammatory cells was a
non-specific finding and that inflammatory myopathy
was unlikely.
Neurogenic changes
The extent of neurogenic atrophy differed between
patients: small angulated fibres were observed in 29/31
(93.5%) cases, small grouped atrophy in 22/31 (71%)
cases, (Figure 1A), pyknotic nuclear clumps in 13/31
(41.9%), increased internalized nuclei in 8/31 (25.8%)
cases and fibre type grouping in 18/31 (58%) cases.
There were NADH densely stained fibres in 27/31 (87%)cases; targetoid fibres in 20/31 (64.5%) cases (Figure 1B);
and moth-eaten fibres in 13/31 (41.9%) cases.
Muscle fibre necrosis and COX negative fibres
Muscle fibre necrosis was seen in five biopsies (16%)
(Figure 1C); only one patient showed increased in CK
level to 1386, two patients with inflammatory infiltrate
and three with uniform over expression of HLA-ABC.
The chronic mononuclear inflammatory cell infiltration
Table 2 Summary of muscle pathology in control patients
Age/sex NC Infl/nec COX -ve fibre HLA C5b-9 P62 TDP
56 F - - - - - - -
54 M - - - - - - -
42 M - - - - - - -
53 F + - - - - - -
67 M - - - - - - -
69 M - - <1% - - - -
67 M - - <1% - - - -
41 M - - - - - - -
49 M - - - - - - -
41 M - - - - - - -
43 F - - - - - - -
65 M - - - - - - -
65 M - - - - - - -
57 M - - - - - - -
50 M - - - - - - -
51 M - - - - - - -
51 F - - - - - - -
64 M - - < 1% - - - -
67 F - - - - - - -
62 F - - - - - - -
NC: neurogenic changes; Infl: inflammation; Nec: Necrosis. C: endomysial
capillaires. F: fibres.
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and E), two of which also showed fibre necrosis, two
with HLA-ABC over expression and two patient with in-
creased CK level to 936 and 1386. In four biopsies there
was more than 1% increase in the proportion of COX
negative fibres (Figure 1F) with rates of 2- 3% . These
cases also contain 1–3 ragged red fibres in the entire bi-
opsy of each case. Although ragged red fibres are useful
in showing abnormal accumulation of mitochondria, the
percentage of COX negative/SDH positive fibres was
more sensitive in identifying fibres with mitochondrial
abnormality in muscle biopsy.
Other changes
Cytoplasmic bodies presented in the form of globular,
irregular, homogenous bodies, best demonstrated on the
Gomori trichrome stain were present in 13/31 (41.9%)
cases.
Immunohistochemistry
The inflammatory infiltrate is mainly composed of lym-
phocytes and few macrophages. The lymphocytes are pre-
dominantly CD3 positive (T lymphocytes). The amount of
inflammatory infiltrate was small in the deeper sections for
the immunostainings for proper quantitative assessment
but there is slight increase of CD4 over CD8 positive Tlymphocytes Immunohistochemistry showed uniform and
sarcolemmal over-expression of HLA-ABC (Figure 1G) in
5/31 (16%) but only few scattered small fibres positive with
neonatal neomysin; therefore excluding HLA-ABC over
expression was due to fibre regeneration and degeneration.
Those five muscles with HLA over expression include two
cases necrosis and one case with a predominantly chronic
mononuclear inflammatory cell infiltration.
In 21/31 (67.7%) muscle biopsies there was granular
deposition of the compliment (C5b-9) in the sarco-
lemma of the atrophic fibres consistent with fibre degen-
eration. However there were 3/31 cases where the C5b-9
antibody deposition was intense in the endomysial
capillaries (Figure 1H) in addition to the presence of an
inflammatory cell infiltration suggesting activation of
compliments.
In the immunohistochemical stains, p62 was positive
in 8/31 (25.8%) cases, displayed as faint, irregular and
granular deposits at the sites of cytoplasmic bodies.
None of the cases show abnormal TDP-43 immunoreac-
tivity or over expression of lysosomal enzyme such as
acid phosphatase; therefore the appearances of p62
reflected a non-specific deposition in fibre degeneration
due to neurogenic changes.
Plasma samples were collected at the time of biopsy,
but assessed for CK levels only after prolonged storage
of the samples (>1 year), so results have an indicative
value rather than providing an absolute quantification.
In three patients there was a marked increase in the
serum CK level (807 IU/L, 1386 IU/L and 963 IU/L). In
two of these cases, the muscle biopsy contained inflam-
matory cells and myofibre necrosis. The CK was mildly
increased (200–500 IU/L) in 12/31 patients; in one of
these patients an inflammatory cell infiltrate was present.
The remaining patients had normal serum CK levels.
The Mann Whitney test shows no significant associ-
ation between CK levels and inflammation (P = 0.33) and
muscle fibre necrosis (P = 0.35).
In the controls all 20 of the muscle biopsies appeared
normal. There was no evidence of neurogenic atrophy,
myofiber necrosis or inflammation. The immunohisto-
chemical staining for HLA Class I and C5b-9 was also
negative in all fibres. In 3/20 biopsies there were occa-
sional COX negative fibres amounting to less than 1%
of total fibres, within normal limits attributed to age-
related changes. Immunohistochemical stains for p62
and TDP-43 were negative.
Discussion
In this large collection of muscle biopsies from patients
with ALS, the predominantn pathological finding is
neurogenic atrophy with a spectrum of findings due to
denervation and re-innervation [34]. The most common
feature of such neurogenic changes is small angulated
Figure 1 (See legend on next page.)
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Figure 1 Pathological changes in the muscles from ALS patients. A: Low power view of muscle with neurogenic changes showing small
and large group atrophy (arrow). B: NADH-TR stain showing atrophic and hyperdense fibres and target fibres (arrow). C: Fibre necrosis (arrow).
D: Inflammatory cell infiltration in the endomysium (arrow) and E: in the perimysium (arrow). F: Cytochrome oxidase negative fibres (arrow).
G: Patchy over expression of HLA) - ABC in muscle fibres. H: Deposition of compliment (C5-9) in the endomysial capillaries.
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are fibre type grouping in nearly 50% of the biopsies and
target fibres in 60% of the biopsies. In many muscle bi-
opsies there is also evidence of disruption of intermyofi-
brillary architecture. Fibre type grouping resulting from
re-innervations of fibres is only present in approximately
50% of our cases. On the other hand the NADH-TR
stain appears to be useful in establishing the neurogenic
changes in showing hyper-dense fibres and targetoid ap-
pearances which is present in 60% of the cases (Figure 1B).
Other findings are an increased number of fibres with
internalized nuclei and pyknotic nuclear clumps. The
ATPase stains confirmed the atrophic fibres are of both
types and not selectively type 2. Though it has been
reported that type 2 fibres are affected by denervation
more rapidly than type 1 fibres in early stages of the
disease process [34], the lack of selective involvement
of fibre type 2 in our cohort may reflect more chronic
disease.
In addition to acute and chronic neurogenic atrophy, a
few cases in our cohort demonstrated additional path-
ology less typical of denervation, such as fibre necrosis,
low grade inflammation, and mitochondrial abnormal-
ities. Albeit infrequent, these changes were not seen in
our cohort of age-matched control biopsies. They are,
nonetheless interesting as alternative theories are raised
regarding the pathogenesis of ALS and involve the periph-
eral rather than the central nervous system. The neuronal
degeneration in the upper and lower motor neurons in
the CNS in ALS may not be the only abnormality and
other cell abnormalities, such as in the muscles or changes
at the neuromuscular junction may play a pathogenic role
[1,22,35-39].
Four of our cases show evidence of mitochondrial ab-
normalities with an increased proportion of cytochrome
oxidase negative fibres (Figure 1F) and few ragged red
fibres beyond that seen in the age-match controls. Mi-
tochondrial alteration has been reported in association
with aging [27,40]; however in these four patients, the
number of CXO negative fibres is seen in higher propor-
tion (2-3%) expected in aging process and three of pa-
tients were in their 60s. This finding is in keeping with
other reports of mitochondrial abnormality in the muscle
of sporadic ALS patients and do not correlate with aging
[15,17,23,41,42]. Mitochondria are known to be involved
in the cellular production of oxygen radicals which play
an important role in cell damage via oxygen/free radicals
in many neurodegenerative diseases [1,16,43-45]. Thereis some evidence of involvement of mitochondria in the
pathogenesis of the ALS. For instance, in experimental
SOD1 mutant mice, there are reports of abnormal
aggregates of mitochondria with vacuolation in skeletal
muscle as well as in the anterior horn cells [18] and
dysfunction of mitochondria in muscle, spinal cord and
liver. Mitochondrial function has an important role to
play in the pathogenesis of the some of the familial
ALS like SOD1 mutation which appears to have toxic
gene of function mutation in copper zinc super-oxide
dysmutase, cytcolic and mitochondrial protein [36,43,46].
However, the nature of any contribution of mitochondrial
abnormalities to human ALS remains uncertain. Abnor-
mal mitochondrial functions have been reported in lym-
phocytes in ALS [11] and mitochondrial DNA deletions
in ALS patients have been described [29,42]. There are
also case reports of ALS and mitochondrial myopathy
[12,16,32,41]. However Echaniz-laguna et al., [23] and
Grehl et al. [47] reported that normal mitochondrial
function is progressively altered with the disease’s pro-
gression secondarily. Recently, Bradley et al. [37] found
no difference in respiratory chain enzyme and deleted
mitochondrial DNA between ALS and controls. The
finding of mitochondrial abnormalities in the biopsies
of few of the ALS patients in this cohort and other pub-
lished studies suggest some link whether primary or
secondary to the pathogenesis of ALS or the ultimate
motor neuron injury [44,48]. It is possible that mito-
chondrial abnormality in the skeletal muscle of sub-
group of ALS patients which does not correlate with
the age and may support the hypothesis that at least in
such cases, mitochondrial dysfunction plays a role in
the pathogenesis of the disease. Subclinical mitochon-
drial dysfunction in subgroups of ALS could also be
present which is otherwise undetectable in the resting
condition and become manifested with further external
and environmental stress such as inflammation and
may contribute to defective axonal transport at neuro
muscular level and to retrograde neuronal degeneration
in few patients.. This suggestion is supported by evi-
dence from Siniliano et al. who reported increased
lactate levels in patient with ALS after exercise [45].
Another interesting finding in muscle biopsies from
our cohort of ALS cases is the presence of fibre necrosis
and low grade inflammatory changes (Figure 1C, D and E).
In five cases, there was evidence of muscle fibre necrosis; a
rare but reported finding in neurogenic atrophy. Inter-
estingly two of these cases showed an inflammatory cell
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we did not find association between presence of mild
inflammation, increased CK levels and clinical mani-
festation and progress of the patient. The inflammatory
process, including the up regulation of HLA- ABC and
compliment deposition (C5b-9) could also be secondary
to neurogenic changes and secondary myofiber necro-
sis. These cases show no evidence for endomysial in-
flammation with invasion of non-necrotic fibres as seen
in inflammatory myopathies or inclusion body myositis
IBM. However, a finding of low grade inflammation in
the muscle is intriguing given evidence that inflammation
in the central nervous system may be a contributory factor
in ALS pathology. There is mounting evidence that acti-
vated microglia and astrocytes, endothelium and lympho-
cytes trafficking in the CNS of ALS patients may play an
etiologic role through the production of molecules, like
IL-6 and TNFalpha and increased oxidative stress [49-52].
Our results may not indicate a primary muscle disease or
inflammation, but it support the view that the low grade
inflammation and sub clinical mitochondrial alteration in
the muscle of some ALS patients may add further burden
in damaging the neuromuscular junctions and contribute
to “dying back” of motor neutrons. The interaction be-
tween the peripheral and central inflammatory process is
critical to understand the its pathogenesis It has been the-
orized that ALS pathology may not necessarily be directly
due to motor neuron degeneration but may start more
distally at the neuromuscular junction. Fischer et al. [53]
showed that the alteration of the neuromuscular junction
led to axonal degeneration and ultimately motor neuron
degeneration in the CNS. Evidence showed that a reduc-
tion in NOGO-A, a neurite outgrowth inhibitor led to in-
crease in the lifespan of SOD1 mice [54,55]. In addition
Bradley et al. [37] showed that myoblasts from ALS
patients exhibit an enhanced sensitivity to oxidative stress.
This evidence suggests that ALS muscle may be particu-
larly vulnerable to additional stress and activate an apop-
totic process [37,56]. Such oxidative stress may come
through different routes such as environmental or even
inflammatory myopathy [39,49,57]. It is possible that in
some ALS patients’ alterations in muscle and the neuro-
muscular junction may be pathogenic contributors result-
ing in retrograde degeneration of the motor neurons. ALS
is a complex and multifactorial disorder with many
potential etiologic and pathogenic mechanisms resulting
in dysfunction at the neuromuscular, axonal and neuronal
levels [1].
Finally, many muscles in this series showed a cytoplas-
mic body which is a known alteration in the intermyofi-
brillary article true in long standing neurogenic changes
expected in ALS patients. Also few cases showed p62
granular deposits but with no over expression lysosomal
enzyme such as acid phosphatase. The appearances arenot specific and reflect process of degeneration in the
muscle fibres. There is no specific well define inclusions
and all the sections were negative with TDP43 stain.Conclusion
In conclusion, acute or chronic neurogenic atrophy is
the nearly uniform finding in this large cohort of muscle
biopsies of ALS patients. In addition, low grade endomy-
sial and perimysial chronic inflammation and mitochon-
drial alterations are seen in a small proportion of muscle
biopsies from patients with sporadic ALS beyond that seen
in age-matched control biopsies. These findings do not ex-
clude the diagnosis of ALS. Neither do these findings meet
criteria for primary inflammatory muscle disease or mito-
chondrial cytopathy. However, these findings could reflect
contributing pathogenic mechanisms whereby additional
oxidative stress by inflammation or other factors could un-
mask subclinical mitochondrial dysfunction in the muscle
of some ALS patients. These muscle biopsy findings from
a relatively large ALS patient cohort, could provide add-
itional clues to understanding the seemingly multifactorial,
complex pathogenesis of ALS.
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